Study #2023-0581
A randomized trial of fecal microbiota transplantation and/or BIOME diet versus placebo in Chimeric antigen receptor T-cell therapy.
MD Anderson Study Status
Enrolling
Treatment Agent
Fecal Microbiota Transplantation
Description
To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma
Study phase:
Phase II
Physician name:
Neeraj Saini
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.